Víctor de Diego1,2, Antonio F Martínez-Monseny3, Jordi Muchart1,2, Daniel Cuadras4, Raquel Montero1,2, Rafael Artuch1,2, Celia Pérez-Cerdá5, Belén Pérez5, Belén Pérez-Dueñas1,2, Andrea Poretti6, Mercedes Serrano7,8,9,10. 1. Neuropediatric, Radiology and Clinical Biochemistry Departments, Hospital Sant Joan de Déu, Barcelona, Spain. 2. U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain. 3. Genetic Medicine and Rare Diseases' Pediatric Institute, Hospital Sant Joan de Déu, Barcelona, Spain. 4. Statistics Department, Fundació Sant Joan de Déu, Barcelona, Spain. 5. Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Universidad Autónoma de Madrid (UAM), U-746 Centre for Biomedical Research on Rare Diseases (CIBER-ER) Madrid, Instituto de Salud Carlos III, IdiPAZ, Madrid, Spain. 6. Section of Pediatric Neuroradiology, Division of Pediatric Radiology, Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MA, USA. 7. Neuropediatric, Radiology and Clinical Biochemistry Departments, Hospital Sant Joan de Déu, Barcelona, Spain. mserrano@hsjdbcn.org. 8. U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain. mserrano@hsjdbcn.org. 9. Genetic Medicine and Rare Diseases' Pediatric Institute, Hospital Sant Joan de Déu, Barcelona, Spain. mserrano@hsjdbcn.org. 10. Neurology Department & Genetic Medicine, Hospital Sant Joan de Déu, and U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Passeig Sant Joan de Déu, 2, 08950, Esplugues, Barcelona, Spain. mserrano@hsjdbcn.org.
Abstract
OBJECTIVE: We aim to delineate the progression of cerebellar atrophy (the primary neuroimaging finding) in children with phosphomannomutase-deficiency (PMM2-CDG) by analyzing longitudinal MRI studies and performing cerebellar volumetric analysis and a 2D cerebellar measurement. METHODS: Statistical analysis was used to compare MRI measurements [midsagittal vermis relative diameter (MVRD) and volume] of children with PMM2-CDG and sex- and age-matched controls, and to determine the rate of progression of cerebellar atrophy at different ages. RESULTS: Fifty MRI studies of 33 PMM2-CDG patients were used for 2D evaluation, and 19 MRI studies were available for volumetric analysis. Results from a linear regression model showed that patients have a significantly lower MVRD and cerebellar volume compared to controls (p < 0.001 and p < 0.001 respectively). There was a significant negative correlation between age and MVRD for patients (p = 0.014). The rate of cerebellar atrophy measured by the loss of MVRD and cerebellar volume per year was higher at early ages (r = -0.578, p = 0.012 and r = -0.323, p = 0.48 respectively), particularly in patients under 11 years (p = 0.004). There was a significant positive correlation between MVRD and cerebellar volume in PMM2-CDG patients (r = 0.669, p = 0.001). CONCLUSIONS: Our study quantifies a progression of cerebellar atrophy in PMM2-CDG patients, particularly during the first decade of life, and suggests a simple and reliable measure, the MVRD, to monitor cerebellar atrophy. Quantitative measurement of MVRD and cerebellar volume are essential for correlation with phenotype and outcome, natural follow-up, and monitoring in view of potential therapies in children with PMM2-CDG.
OBJECTIVE: We aim to delineate the progression of cerebellar atrophy (the primary neuroimaging finding) in children with phosphomannomutase-deficiency (PMM2-CDG) by analyzing longitudinal MRI studies and performing cerebellar volumetric analysis and a 2D cerebellar measurement. METHODS: Statistical analysis was used to compare MRI measurements [midsagittal vermis relative diameter (MVRD) and volume] of children with PMM2-CDG and sex- and age-matched controls, and to determine the rate of progression of cerebellar atrophy at different ages. RESULTS: Fifty MRI studies of 33 PMM2-CDGpatients were used for 2D evaluation, and 19 MRI studies were available for volumetric analysis. Results from a linear regression model showed that patients have a significantly lower MVRD and cerebellar volume compared to controls (p < 0.001 and p < 0.001 respectively). There was a significant negative correlation between age and MVRD for patients (p = 0.014). The rate of cerebellar atrophy measured by the loss of MVRD and cerebellar volume per year was higher at early ages (r = -0.578, p = 0.012 and r = -0.323, p = 0.48 respectively), particularly in patients under 11 years (p = 0.004). There was a significant positive correlation between MVRD and cerebellar volume in PMM2-CDGpatients (r = 0.669, p = 0.001). CONCLUSIONS: Our study quantifies a progression of cerebellar atrophy in PMM2-CDGpatients, particularly during the first decade of life, and suggests a simple and reliable measure, the MVRD, to monitor cerebellar atrophy. Quantitative measurement of MVRD and cerebellar volume are essential for correlation with phenotype and outcome, natural follow-up, and monitoring in view of potential therapies in children with PMM2-CDG.
Authors: P Feraco; M Mirabelli-Badenier; M Severino; M G Alpigiani; M Di Rocco; R Biancheri; A Rossi Journal: AJNR Am J Neuroradiol Date: 2012-06-21 Impact factor: 3.825
Authors: E Aronica; A A M W van Kempen; M van der Heide; B T Poll-The; H J van Slooten; D Troost; J M Rozemuller-Kwakkel Journal: Acta Neuropathol Date: 2005-02-16 Impact factor: 17.088
Authors: Rita Barone; M Carrozzi; R Parini; R Battini; D Martinelli; M Elia; M Spada; F Lilliu; G Ciana; A Burlina; V Leuzzi; M Leoni; L Sturiale; G Matthijs; J Jaeken; M Di Rocco; D Garozzo; A Fiumara Journal: J Neurol Date: 2014-10-30 Impact factor: 4.849
Authors: Carsten Lukas; Barbara Bellenberg; Odo Köster; Sebastian Greschner; Horst K Hahn Journal: Psychiatry Res Date: 2011-06-15 Impact factor: 3.222
Authors: B Pérez-Dueñas; A García-Cazorla; M Pineda; P Poo; J Campistol; V Cusí; E Schollen; G Matthijs; S Grunewald; P Briones; C Pérez-Cerdá; R Artuch; M A Vilaseca Journal: Eur J Paediatr Neurol Date: 2008-10-22 Impact factor: 3.140
Authors: Natalia Lourdes Serrano; Victor De Diego; Daniel Cuadras; Antonio F Martinez Monseny; Ramón Velázquez-Fragua; Laura López; Ana Felipe; Luis G Gutiérrez-Solana; Alfons Macaya; Belén Pérez-Dueñas; Mercedes Serrano Journal: Orphanet J Rare Dis Date: 2017-09-15 Impact factor: 4.123
Authors: Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira Journal: Int J Mol Sci Date: 2018-04-27 Impact factor: 5.923
Authors: Mercè Izquierdo-Serra; Antonio F Martínez-Monseny; Laura López; Julia Carrillo-García; Albert Edo; Juan Darío Ortigoza-Escobar; Óscar García; Ramón Cancho-Candela; M Llanos Carrasco-Marina; Luis G Gutiérrez-Solana; Daniel Cuadras; Jordi Muchart; Raquel Montero; Rafael Artuch; Celia Pérez-Cerdá; Belén Pérez; Belén Pérez-Dueñas; Alfons Macaya; José M Fernández-Fernández; Mercedes Serrano Journal: Int J Mol Sci Date: 2018-02-22 Impact factor: 5.923
Authors: Antonio F Martínez-Monseny; Albert Edo; Dídac Casas-Alba; Mercè Izquierdo-Serra; Mercè Bolasell; David Conejo; Loreto Martorell; Jordi Muchart; Laura Carrera; Carlos I Ortez; Andrés Nascimento; Baldo Oliva; José M Fernández-Fernández; Mercedes Serrano Journal: Int J Mol Sci Date: 2021-05-13 Impact factor: 5.923